卡波济肉瘤临床治疗研究进展  

Progress in clinical treatment of Kaposi sarcoma

作　　者：陆飞燕 曾怡 赵丽娟 LU Feiyan;ZENG Yi;ZHAO Lijuan(Department of Pathogenic Microbiology and Immunology of Youjiang Medical University for Nationalities,Baise 533000,China)

机构地区：[1]右江民族医学院基础医学院病原生物学与免疫学教研室,广西百色533000

出　　处：《实用医学杂志》2020年第21期3013-3017,共5页The Journal of Practical Medicine

基　　金：广西自然科学基金面上项目(项目编号:2014GXNSFAA118136);2020年右江民族医学院研究生创新计划项目(项目编号:YXCXJH2020001)。

摘　　要：卡波济肉瘤(Kaposi sarcoma,KS)是一种侵袭性淋巴血管增生性肿瘤,其发生与卡波济肉瘤相关疱疹病毒(Kaposi sarcoma-associated herpesvirus,KSHV)感染内皮细胞密切相关。由KSHV引发的KS是艾滋病常见的并发性恶性肿瘤,多见于地中海和非洲地区,死亡率较高。卡波济肉瘤的治疗是临床面临的难题之一,近年来KS的治疗取得一定突破,尤其是联合抗逆转录病毒治疗(CART)问世后,KS发病率显著下降,患者预后得到明显改善。本文就卡波济肉瘤的临床治疗研究进展进行综述。Kaposi′s sarcoma(KS)is an aggressive lymphoangioproliferative tumor.Its occurrence is closely related to the infection of endothelial cells by Kaposi sarcoma associated herpesvirus(KSHV).KS caused by KSHV is a common concurrent malignant tumor of AIDS,which is more common in Mediterranean and Africa,with high mortality.The treatment of Kaposi sarcoma is one of the difficult problems in clinical practice.In recent years,KS has achieved a breakthrough.Especially after the advent of CART,the incidence rate of KS has decreased significantly,and the prognosis of patients has improved significantly.This article reviews the progress of clinical treatment of Kaposi′s sarcoma.

关 键 词：卡波济肉瘤 KSHV 卡波济肉瘤治疗 CART 

分 类 号：R733.4[医药卫生—肿瘤]